TICKERNERD
Menu
ISRGISRGHealthcare · Medical Instruments & Supplies

ISRG Stock Forecast: Intuitive Surgical, Inc. Price Predictions for 2026-2027

Last close, 21 Sept 2026
$402
+2.12% on the day

The 32 Wall Street analysts covering Intuitive Surgical, Inc. hold a median 12-month price target of $483 — +20.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 75 of 100 as at 21 Sept 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$143.9B
Ticker Nerd rank
75 / 100
Median analyst target
$483
Analysts covering
32
Revenue$2.9B+18.5% y/y
Operating income$971.9M
Net income$823.2M
Free cash flow$948.4M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+6.3%
1M
+6.0%
YTD
−29.1%
1Y
−8.4%
From 52W high
−32.3%
From 52W low
+21.0%
$332
$593
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ISRG stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Intuitive Surgical, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Sept 2026
75 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Quality
94
Revisions
93
Issuance
76
Growth
69
Volatility
66
Value
66
Accruals
40
Momentum
33
Size
2

Quality (94): The business earns solid, repeatable profits on what it owns.

Momentum (33): The shares have been drifting down relative to others.

Size (2): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

ISRG stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ISRG, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$300$400$500$600$700Oct 25Jan 26Apr 26Jul 26ISRGHigh $685Median $483Low $324

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says32 analysts
24 Buy7 Hold1 Sell
Low $324Median $483High $685

The green dot is the last close — the median target sits +20.3% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 0 moved their price target up and 8 moved it down.

DateFirmActionRatingTarget
8 Sept 2026BTIGReiteratesBuy$469
12 Aug 2026OppenheimerUpgradeOutperform$500
12 Aug 2026OppenheimerUpgradeOutperform—
30 July 2026HSBCDowngradeHold$931
30 July 2026HSBCDowngradeHold—
28 July 2026UBSAssumesBuy$550 → $500
17 July 2026BairdMaintainsOutperform—
17 July 2026BairdMaintainsOutperform$525 → $500
17 July 2026BernsteinMaintainsOutperform$750 → $685
17 July 2026BernsteinMaintainsOutperform—
17 July 2026BTIGMaintainsBuy$512 → $469
17 July 2026BTIGMaintainsBuy—
17 July 2026CitigroupMaintainsBuy—
17 July 2026CitigroupMaintainsBuy$590 → $500
17 July 2026Evercore ISI GroupMaintainsIn-Line—
17 July 2026Evercore ISI GroupMaintainsIn-Line$430 → $375
17 July 2026JP MorganMaintainsOverweight—
17 July 2026JP MorganMaintainsOverweight$550 → $450
17 July 2026Leerink PartnersMaintainsOutperform$573 → $454
17 July 2026Leerink PartnersMaintainsOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ISRG appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

ISRG vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 21 Sept 2026, Intuitive Surgical, Inc. returned −8.4% against +17.8% for the S&P 500, dividends included.

ISRG vs S&P 500, last 12 monthsTotal return, rebased to 100
708090100110120130Oct 25Jan 26Apr 26Jul 26ISRGS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ISRG analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+3.5%
Analysts raising
1
Analysts cutting
0
Fundamentals

Intuitive Surgical, Inc. (ISRG) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
46.0×

Cheaper than 16% of US stocks

Price / sales
13.0×

Cheaper than 12% of US stocks

Price / book
7.8×

Cheaper than 12% of US stocks

EV / EBITDA
32.7×

Cheaper than 8% of US stocks

Growth & margins
Revenue growth (YoY)
18.5%

Higher than 67% of US stocks

Earnings growth (YoY)
24.3%

Higher than 62% of US stocks

Gross margin
67.8%

Higher than 81% of US stocks

Operating margin
33.6%

Higher than 89% of US stocks

Net margin
28.4%

Higher than 88% of US stocks

Returns & dividend
Return on equity
17.4%

Higher than 78% of US stocks

Return on assets
10.5%

Higher than 93% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Intuitive Surgical, Inc. (ISRG) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Intuitive Surgical, Inc. has a market value of $143.9B and an enterprise value of $136.8B.

  • Revenue in the twelve months to 30 June 2026: $11.0B. The latest quarter grew 18.5% year on year.

  • Net income over the same four quarters: $3.2B, a 28.6% net margin.

  • Diluted earnings per share, trailing twelve months: $8.73.

  • Free cash flow in the twelve months to 30 June 2026: $3.2B, after $483.8M of capital spending.

  • Intuitive Surgical, Inc. spent $3.6B on share buybacks in the twelve months to 30 June 2026.

  • Shares outstanding: 353.9M.

  • Trailing P/E: 46.0×; forward P/E: 33.2× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Intuitive Surgical, Inc. employs 17,021 people — $648K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 22 Sept 2026

Data provided by Twelve Data

Peers

ISRG vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Instruments & Supplies
CompanyMarket capTKN rank
ISRGIntuitive Surgical, Inc.$143.9B
75
BDXBecton, Dickinson & Co.$49.8B
93
MDLNMedline, Inc.$42.0B
19
RMDResMed, Inc.$32.6B
70
ALCAlcon AG$32.3B
68
WSTWest Pharmaceutical Services, Inc.$26.0B
94
SOLVSolventum Corp.$15.4B
90

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Intuitive Surgical, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ISRG news & analysis

Abbott Laboratories vs. Intuitive Surgical: Recent Quarterly Revenue Trends Reveal a Classic Investing Truth

The Motley Fool · 21 Sept 2026neutral

The Motley Fool compares Abbott Laboratories and Intuitive Surgical based on recent quarterly revenue trends to illustrate a classic investing principle. The article outlines Abbott's diverse business model, which spans medical devices, diagnostics, nutrition, and generic pharmaceuticals.

Why it matters — ISRG watchers would care because the comparison highlights how revenue diversification and business models affect investor perceptions of growth-oriented companies like Intuitive Surgical.

Ambulatory Surgery Centers Are Becoming ISRG's New Growth Engine

Zacks Investment Research · 21 Sept 2026positive

Intuitive Surgical is expanding robotic surgery into ambulatory surgery centers, using lower-cost XiR systems to reach new customers and support outpatient procedures. This opens access to a wider base of facilities beyond traditional hospital settings.

Why it matters — A ISRG watcher would care because expanding into ambulatory surgery centers could broaden the company's customer base and extend its robotic-surgery footprint into the growing outpatient care market.

ISRG Wins EU Nod to Expand da Vinci SP in Gynecologic Procedures

Zacks Investment Research · 16 Sept 2026positive

Intuitive Surgical received CE mark approval in Europe to expand its da Vinci SP system into transvaginal gynecologic procedures. This regulatory nod broadens the platform's approved indications in the European market.

Why it matters — The expanded CE mark opens a new women's health opportunity for ISRG, adding a potential growth avenue for its da Vinci SP platform in Europe.

Intuitive Surgical, Inc. (ISRG) is Attracting Investor Attention: Here is What You Should Know

Zacks Investment Research · 16 Sept 2026neutral

Zacks.com reports that users have been paying close attention to Intuitive Surgical (ISRG), prompting an examination of the stock. The item notes the increased investor interest and what it may indicate about the company.

Why it matters — ISRG watchers would care because growing investor attention signals heightened market interest in the company's recent developments and outlook.

ISRG's da Vinci Study Shows Better Outcomes Across 13 Common Conditions

Zacks Investment Research · 15 Sept 2026positive

Zacks reports that Intuitive Surgical's da Vinci system was evaluated in a meta-analysis covering 14 million procedures, finding better perioperative outcomes across 13 common conditions compared with laparoscopic and open surgery. The study highlights improved results associated with the da Vinci platform.

Why it matters — The study offers clinical evidence supporting the da Vinci system's outcomes, which may be relevant to Intuitive Surgical investors assessing the platform's competitive position.

FAQ

Frequently asked questions about ISRG stock

What is the ISRG stock price forecast for 2026-2027?

The 32 Wall Street analysts covering Intuitive Surgical, Inc. have a median 12-month price target of $483, with estimates ranging from $324 to $685. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ISRG stock a buy right now?

Of the 32 analysts covering Intuitive Surgical, Inc., 24 rate it a Buy, 7 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Intuitive Surgical, Inc. 75 out of 100 across roughly 4,600 US stocks as at 21 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ISRG?

As at 21 Sept 2026, Intuitive Surgical, Inc. ranks 75 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (94 of 100).

Will ISRG stock go up?

No one can know that. What the data says: the median 12-month target from 32 analysts implies +20.3% from the last close, and Ticker Nerd's factor model ranks Intuitive Surgical, Inc. 75 out of 100 as at 21 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ISRG stock forecast for 2030?

No analyst covering Intuitive Surgical, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ISRG are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $324 to $685 over the next 12 months.

How has ISRG stock performed over the past year?

Intuitive Surgical, Inc. returned -8.4% over the 12 months to 21 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Intuitive Surgical, Inc. do?

Intuitive Surgical Inc. is a medical technology company focused on robotic-assisted and minimally invasive care.

What is the latest news on ISRG?

The most recent item we track (The Motley Fool, 21 Sept 2026): "Abbott Laboratories vs. Intuitive Surgical: Recent Quarterly Revenue Trends Reveal a Classic Investing Truth". The Motley Fool compares Abbott Laboratories and Intuitive Surgical based on recent quarterly revenue trends to illustrate a classic investing principle. The article outlines Abbott's diverse business model, which spans medical devices, diagnostics, nutrition, and generic pharmaceuticals.

Company

About Intuitive Surgical, Inc.

Intuitive Surgical Inc. is a medical technology company focused on robotic-assisted and minimally invasive care. Intuitive Surgical develops, manufactures, and markets the da Vinci surgical systems, which are used by surgeons to perform procedures with enhanced precision through a minimally invasive approach. The company also offers the Ion endoluminal system, extending its platform into diagnostic endoluminal procedures and lung biopsy applications. In addition to its core systems, Intuitive Surgical supports hospitals and healthcare providers with instruments, accessories, and services that help integrate robotic surgery into clinical workflows. Its products serve a broad range of specialties, including general surgery, urology, gynecology, thoracic surgery, and diagnostic care. Headquartered in Sunnyvale, California, Intuitive Surgical plays a significant role in the global healthcare equipment market by advancing the adoption of robotic systems in modern surgical and diagnostic settings.

CEO Mr. David J. Rosa · 17,021 employees · United States · https://www.intuitive.com